Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:antineoplastic_agent |
| gptkbp:ATCCode |
gptkb:L01XX43
|
| gptkbp:CASNumber |
75747-14-7
|
| gptkbp:category |
gptkb:benzoquinone_ansamycin
antitumor antibiotic |
| gptkbp:chemicalFormula |
C31H43N3O8
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:derivedFrom |
gptkb:geldanamycin
|
| gptkbp:IUPACName |
gptkb:17-allylamino-17-demethoxygeldanamycin
|
| gptkbp:mechanismOfAction |
Hsp90 inhibitor
|
| gptkbp:molecularWeight |
585.7 g/mol
|
| gptkbp:otherName |
gptkb:Tanespimycin
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL25422
3081363 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:targets_protein |
gptkb:Hsp90
|
| gptkbp:UNII |
QX8U5KJ8QG
|
| gptkbp:used_in |
cancer research
|
| gptkbp:bfsParent |
gptkb:HSP90
|
| gptkbp:bfsLayer |
7
|
| http://www.w3.org/2000/01/rdf-schema#label |
17-AAG
|